Although hormonal receptors expression, cancer stage, and adjuvant trastuzumab therapy were all known prognostic factors for HER2-positive breast cancer, multivariate analyses revealed stomatin was an independent factor for cancer metastases (p = 0.017, Table 2) for stage I-III HER2-positive breast cancers. Here, NR4A1 is linked to breast cancer.